DFTX NASDAQ
Definium Therapeutics, Inc.
1W: +3.4%
1M: -3.9%
3M: -15.6%
YTD: +174.2%
$37.40
-0.20 (-0.53%)
Weekly Expected Move ±7.4%
$32
$35
$37
$40
$43
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.54
Bearish
1 bullish
0 neutral
4 bearish
Articles (7d)
5
Daily Sentiment (7 Days)
Articles (100)
-inc-logo-1200x675.jpg?v=20240515130629){kind=logo}
Definium Therapeutics (NASDAQ:DFTX) Insider Matthew Wiley Sells 3,097 Shares of Company Stock
Definium Therapeutics (NASDAQ:DFTX) CFO Brandi Roberts Sells 3,377 Shares of Company Stock
Definium Therapeutics (NASDAQ:DFTX) Insider Mark Sullivan Sells 14,051 Shares of Stock
Definium Therapeutics (NASDAQ:DFTX) CEO Robert Barrow Sells 31,550 Shares of Company Stock
Corient Private Wealth LP Acquires New Position in Definium Therapeutics, Inc. $DFTX
Sequoia Financial Advisors LLC Invests $812,000 in Definium Therapeutics, Inc. $DFTX
10 mid-cap healthcare stocks with the strongest momentum grades
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Definium Reports Second Phase III Success in Anxiety Disorder Program
Definium rises as LSD pill achieves primary goal in late-stage trial for anxiety
At a glance: stocks gapping up premarket
FDA names acting heads of drug and vaccine units to permanent roles
Definium succeeds in late-stage trial for LSD-derived psychiatric therapy
Wall Street Analysts See a 34.86% Upside in Definium Therapeutics, Inc. (DFTX): Can the Stock Really Move This High?
Wall Street Analysts See a 34.86% Upside in Definium Therapeutics, Inc. (DFTX): Can the Stock Really Move This High?
Notable healthcare headlines for the week: UnitedHealth, J&J, and Intuitive Surgical in focus
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet
Psychedelic drugmakers could get boost from HHS, VA memorandum
Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?
Definium Therapeutics (NASDAQ: DFTX) raises $758M net in equity sale - Stock Titan
DFTX Stock Soars On Breakthrough Phase 3 Depression Data - timothysykes.com
Definium Therapeutics (DFTX) Sees 21.8% Surge in Stock Price - GuruFocus
DFTX Stock Soars After Phase 3 Depression Trial Win - StocksToTrade
DFTX Stock Soars After Phase 3 Depression Trial Win - timothysykes.com
Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120 - simplywall.st
To Wall Street, psychedelics biotechs are more teammates than rivals
Definium Therapeutics Prices Upsized $700 Million Share Offering - marketscreener.com
Why Definium Therapeutics (DFTX) Is Up 49.8% After DT120 Phase 3 Win And $700 Million Raise
Definium Therapeutics prices $700M upsized public offering at $34.00 a share
Definium Therapeutics (DFTX) Posts Phase 3 Win And Plans Public Offering
Definium Therapeutics (DFTX) Posts Phase 3 Win And Plans Public Offering - Yahoo Finance
Definium Therapeutics raises $700M in stock sale, with more shares possible - Stock Titan
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
What's Going On With Definium Therapeutics Stock Tuesday? - Benzinga
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals - Yahoo Finance
Definium Therapeutics (DFTX) Stock Could Be 30.5% Undervalued After Positive Phase 3 Data - Sahm
Definium Therapeutics (DFTX) Hits New High on Impressive Drug Candidate Trial
Definium Therapeutics (DFTX) Hits New High on Impressive Drug Candidate Trial - Yahoo Finance
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Yahoo Finance
This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.
Definium Therapeutics, Inc. Announces Proposed Public Offering
Top Midday Gainers
Definium Therapeutics shares surge on positive late-stage trial results for LSD-based depression therapy
Definium Therapeutics Stock (DFTX) Rockets on a Phase 3 Trial Win - TipRanks
Definium Therapeutics stock hits 52-week high at 38.74 USD By Investing.com - Investing.com Canada
Transcript : Definium Therapeutics, Inc. - Shareholder/Analyst Call - marketscreener.com
Definium Therapeutics Inc. (DFTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Benzinga
Definium Therapeutics (DFTX) Reports Positive Phase 3 Study Resu - GuruFocus
Definium's depression pill posts Phase 3 win, with 8.1-point gap - Stock Titan
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results — What Investors Need To Know - Yahoo Finance
DFTX Stock Rallies Ahead Of High-Stakes Phase 3 Depression Drug Trial Results — What Investors Need To Know
Definium sets webcast on Phase 3 depression study results for June 22 - Stock Titan
Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
How Definium’s US$247 Million Shelf and New Equity Grants At Definium Therapeutics (DFTX) Have Changed Its Investment Story - simplywall.st
Definium Therapeutics (DFTX) director receives RSU and stock option grants - Stock Titan
Definium Therapeutics (DFTX) director receives RSU and stock option grants - Stock Titan
Definium Therapeutics Announces New Employee Inducement Grants
Six new Definium hires receive options on 155,480 shares - Stock Titan
A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum
A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum - Yahoo Finance
Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period (2026-2036) Driven by Innovative Therapies | DelveInsight
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent?
Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent? - Yahoo Finance
Definium Therapeutics Q1 Earnings Call Highlights
Definium (DFTX) Q1 2026 Earnings Transcript
Definium (DFTX) Q1 2026 Earnings Transcript
Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Three late-stage psychiatry trial readouts due as Definium adds PTSD - Stock Titan
A Look At Definium Therapeutics (DFTX) Valuation As DT120 ODT Nears Key Phase 2 And Phase 3 Readouts
Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
These 3 Psychedelic Stocks Activated After Trump's Executive Order
Q1 Earnings Estimate for DFTX Issued By HC Wainwright
Definium Therapeutics Investor Day: DT120 Phase III Readouts Set for Late Q2–Q3, PTSD Plan for 2027
The Bull Case For Definium Therapeutics (DFTX) Could Change Following US Psychedelic Policy Momentum - Yahoo Finance
Trump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to Soar
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research
Biggest stock movers Monday: Psychedelic stocks and more
Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains
Trump issues executive order on psychedelic drugs
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst
Shroom stocks rise as Trump is said to sign executive order on psychedelic drug
Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Rating of “Buy” by Analysts
Definium Therapeutics, Inc. (NASDAQ:DFTX) Short Interest Update
A Look At Definium Therapeutics (DFTX) Valuation After Its Recent Name Change And Share Price Momentum - Yahoo Finance
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names
Ally Bridge Group NY LLC Sells 364,728 Shares of Definium Therapeutics, Inc. $DFTX
Equities Analysts Set Expectations for DFTX Q1 Earnings